Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

Blood (2014) 123 (10): 1470–1478.

https://doi.org/10.1182/blood-2013-10-532598

Published: 2014

Includes: Supplemental data

Journal Articles

A Childhood Leukaemia Cluster in Milan: Possible Role of Pandemic AH1N1 Swine Flu Virus.

Giovanni Cazzaniga, PhD, Luigi A. Bisanti, Chiara Palmi, PhD, Giorgia Randi, Fabrizio Pregliasco, Silvia Deandrea, Silvia Bungaro, Maria Grazia Valsecchi, Giuseppe Masera, Andrea Biondi, MD, Mel Greaves, MD, PhD

Blood (2012) 120 (21): 2496.

https://doi.org/10.1182/blood.V120.21.2496.2496

Published: 2012

Journal Articles

Results of the Randomized I-BFM-SG Trial „Acute Lymphoblastic Leukemia Intercontinental-BFM 2002“ in 5060 Children Diagnosed in 15 Countries on 3 Continents

Blood (2011) 118 (21): 872.

https://doi.org/10.1182/blood.V118.21.872.872

Published: 2011

Journal Articles

Detection of CALM-AF10 Fusion Transcript Does Not Predict A Poor Prognosis in Children with T-Lineage Acute Lymphoblastic Leukemia Treated with AIEOP ALL 2000 Protocol and Subsequent Modified 2000 Study (R-2006).

Blood (2009) 114 (22): 1578.

https://doi.org/10.1182/blood.V114.22.1578.1578

Published: 2009

Journal Articles

Results of the AIEOP-BFM ALL 2000 Study for Childhood Acute Lymphoblastic Leukemia IN AIEOP High Risk Patients.

Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Maurizio Aricò, Carmelo Rizzari, Rosanna Parasole, Chiara Messina, Giulio De Rossi, Elena Barisone, Luca Lo Nigro, Nicola Santoro, Ottavio Ziino, Franco Locatelli, Andrea Pession, Anna Maria Testi, Concetta Micalizzi, Andrea Biondi, Giuseppe Basso, Daniela Silvestri, Giuseppe Masera, MD

Blood (2009) 114 (22): 319.

https://doi.org/10.1182/blood.V114.22.319.319

Published: 2009

Journal Articles

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study.

Andrea Biondi, André Schrauder, Maria Grazia Valsecchi, Claus R Bartram, Georg Mann, Giulio De Rossi, Anja Möricke, Rosanna Parasole, Jochen Harbott, Chiara Messina, C. Rizzari, Giuseppe Masera, Martin Schrappe

Blood (2008) 112 (11): 1511.

https://doi.org/10.1182/blood.V112.11.1511.1511

Published: 2008

Journal Articles

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study.

Valentino Conter, MD, André Schrauder, MD, Helmut Gadner, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Michael Dvorzak, MD, Andrea Biondi, MD, Claus R. Bartram, PhD, Giuseppe Basso, MD, Martin Stanulla, MD, Maurizio Aricò, MD, Karl Welte, MD, Giuseppe Masera, MD, Martin Schrappe, MD

Blood (2007) 110 (11): 544.

https://doi.org/10.1182/blood.V110.11.544.544

Published: 2007

Journal Articles

Early Evaluation of Bone Marrow Minimal Residual Disease by Flowcytometry on Day 15 Is Feasible on a Multicenter Basis and Bears Strong Prognostic Value in Childhood Acute Lymphoblastic Leukemia. The AIEOP-BFM Experience.

Giuseppe Basso, Giuseppe Gaipa, Maria Grazia Valsecchi, Marinella Veltroni, Michael Dworzak, Richard Ratei, Daniela Silvestri, Alessandra Benetello, Giuseppe Masera, Valentino Conter, Maurizio Arico, Andrea Biondi

Blood (2007) 110 (11): 1423.

https://doi.org/10.1182/blood.V110.11.1423.1423

Published: 2007

Journal Articles

Long Term Results of the AIEOP-All-95 Trial for Childhood Acute Lymphoblastic Leukemia. An Insight on the Prognostic Value of Dna Index in the Frame of BFM-Based Chemotherapy.

Maurizio Arico, Maria Grazia Valsecchi, Carmelo Rizzari, Elena Barisone, Andrea Biondi, Fiorina Casale, Franco Locatelli, Luca Lo Nigro, Matteo Luciani, Chiara Messina, Concetta Micalizzi, Rosanna Parasole, Andrea Pession, Nicola Santoro, Anna Maria Testi, Daniela Silvestri, Giuseppe Basso, Giuseppe Masera, Valentino Conter

Blood (2007) 110 (11): 1440.

https://doi.org/10.1182/blood.V110.11.1440.1440

Published: 2007

Journal Articles

TEL/AML1 Rearrangement Is Rare in Children with Acute Lymphoblastic Leukemia (ALL) and Down Syndrome (DS). Presenting Features and Treatment Outcome in the Experience of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).

Blood (2007) 110 (11): 848.

https://doi.org/10.1182/blood.V110.11.848.848

Published: 2007

Journal Articles

High Dose Methotrexate (HD MTX at 2 gr/sqm x 4) Associated to Extended Intrathecal (IT) Chemotherapy Is Effective for Prevention of Central Nervous System (CNS) Relapse in Childhood ALL Treated with BFM Systemic Therapy.

Blood (2005) 106 (11): 10.

https://doi.org/10.1182/blood.V106.11.10.10

Published: 2005

Journal Articles

Vincristine (VCR) - Dexamethasone (DEXA) Pulses for Intermediate Risk (IR) Childhood Acute Lymphoblastic Leukemia (ALL) Treated with BFM Based Protocols: Results of the I-BFM-SG ALL IR 95 Study.

Valentino Conter, Maria Grazia Valsecchi, Daniela Silvestri, Myriam Campbell, Eduardo A. Dibar, Edina Magyarosy, Helmut Gadner, Jan Stary, Yves Benoit, Hansjoerg Riehm, Giuseppe Masera, Martin Schrappe

Blood (2005) 106 (11): 11.

https://doi.org/10.1182/blood.V106.11.11.11

Published: 2005

Journal Articles

Children with TEL/AML1-Positive Acute Lymphoblastic Leukemia (ALL) and Favorable Presenting Features May Benefit from the Use of Vincristine-Dexamethasone (VCR-DXM) Pulses on Top of Antimetabolite-Based Continuation Therapy.

Blood (2005) 106 (11): 9.

https://doi.org/10.1182/blood.V106.11.9.9

Published: 2005

Journal Articles

Acute Lymphoblastic Leukemia in Children with Associated Genetic Conditions Other Than Down Syndrome. The AIEOP Experience.

Ottavio Ziino, Roberto Rondelli, Fulvio Porta, Rossella Mura, Concetta Micalizzi, Valentino Conter, Marie France Pinta Boccalatte, Chiara Messina, Matteo Luciani, Elena Barisone, Franco Locatelli, Andrea Pession, Giuseppe Basso, Andrea Biondi, Giuseppe Masera, Maurizio Aricò

Blood (2005) 106 (11): 863.

https://doi.org/10.1182/blood.V106.11.863.863

Published: 2005

Journal Articles

Treatment Intensification of Traditional BFM Therapy with 3 Chemotherapy Blocks and Double Delayed Intensification (Protocol II) Improves Outcome in Infants with High Risk (HR) Acute Lymphoblastic Leukemia (ALL): Results of Two Consecutive AIEOP Studies.

Carmelo Rizzari, Maria Grazia Valsecchi, Paola De Lorenzo, Maurizio Aricò, Giuseppe Basso, Franco Locatelli, Luca Lo Nigro, Giulio De Rossi, Giuseppe Masera, Andrea Biondi

Blood (2005) 106 (11): 871.

https://doi.org/10.1182/blood.V106.11.871.871

Published: 2005

Journal Articles

Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group.

Blood (2004) 104 (11): 392.

https://doi.org/10.1182/blood.V104.11.392.392

Published: 2004

Journal Articles

Difference in Outcome of Adolescents with Acute Lymphoblastic Leukemia (ALL) Enrolled in Pediatric (AIEOP) and Adult (GIMEMA) Protocols.

Anna Maria Testi, MD, Maria Grazia Valsecchi, MD, Valentino Conter, MD, Marco Vignetti, MD, Francesca Paoloni, BSc, Fiorina Giona, MD, Maria Luisa Moleti, MD, Luca Lo Nigro, MD, Franco Locatelli, MD, Saverio La Dogana, MD, Giorgina Specchia, MD, Francesca Fabiano, MD, Anna Recchia, MD, Franco Mandelli, MD, Robert Foa’, MD, Giuseppe Masera

Blood (2004) 104 (11): 1954.

https://doi.org/10.1182/blood.V104.11.1954.1954

Published: 2004

Journal Articles

Three-Drug Induction and BFM-Type Intensive Consolidation Chemotherapy for Treatment of Standard Risk Childhood Acute Lymphoblastic Leukemia Defined Also by DNA index. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Study ALL-9501.

Maurizio Arico’, Valentino Conter, Maria Grazia Valsecchi, Marie France Pinta Boccalatte, Elena Barisone, Chiara Messina, Giulio De Rossi, Luca Lo Nigro, Andrea Pession, Franco Locatelli, Concetta Micalizzi, Giuseppe Basso, Giuseppe Masera

Blood (2004) 104 (11): 1951.

https://doi.org/10.1182/blood.V104.11.1951.1951

Published: 2004

Journal Articles

Genetic evidence for lineage-related and differentiation stage–related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia

Marco Tartaglia, Simone Martinelli, Giovanni Cazzaniga, Viviana Cordeddu, Ivano Iavarone, Monica Spinelli, Chiara Palmi, Claudio Carta, Andrea Pession, Maurizio Aricò, Giuseppe Masera, Giuseppe Basso, Mariella Sorcini, Bruce D. Gelb, Andrea Biondi

Blood (2004) 104 (2): 307–313.

https://doi.org/10.1182/blood-2003-11-3876

Published: 2004

Includes: Supplemental data

Journal Articles

Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II

Maurizio Aricò, Maria Grazia Valsecchi, Valentino Conter, Carmelo Rizzari, Andrea Pession, Chiara Messina, Elena Barisone, Vincenzo Poggi, Giulio De Rossi, Franco Locatelli, Maria Concetta Micalizzi, Giuseppe Basso, Giuseppe Masera

Blood (2002) 100 (2): 420–426.

https://doi.org/10.1182/blood.V100.2.420

Published: 2002

NARROW

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

A Childhood Leukaemia Cluster in Milan: Possible Role of Pandemic AH1N1 Swine Flu Virus.

Results of the Randomized I-BFM-SG Trial „Acute Lymphoblastic Leukemia Intercontinental-BFM 2002“ in 5060 Children Diagnosed in 15 Countries on 3 Continents

Detection of CALM-AF10 Fusion Transcript Does Not Predict A Poor Prognosis in Children with T-Lineage Acute Lymphoblastic Leukemia Treated with AIEOP ALL 2000 Protocol and Subsequent Modified 2000 Study (R-2006).

Results of the AIEOP-BFM ALL 2000 Study for Childhood Acute Lymphoblastic Leukemia IN AIEOP High Risk Patients.

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study.

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study.

Early Evaluation of Bone Marrow Minimal Residual Disease by Flowcytometry on Day 15 Is Feasible on a Multicenter Basis and Bears Strong Prognostic Value in Childhood Acute Lymphoblastic Leukemia. The AIEOP-BFM Experience.

Long Term Results of the AIEOP-All-95 Trial for Childhood Acute Lymphoblastic Leukemia. An Insight on the Prognostic Value of Dna Index in the Frame of BFM-Based Chemotherapy.

TEL/AML1 Rearrangement Is Rare in Children with Acute Lymphoblastic Leukemia (ALL) and Down Syndrome (DS). Presenting Features and Treatment Outcome in the Experience of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).

High Dose Methotrexate (HD MTX at 2 gr/sqm x 4) Associated to Extended Intrathecal (IT) Chemotherapy Is Effective for Prevention of Central Nervous System (CNS) Relapse in Childhood ALL Treated with BFM Systemic Therapy.

Vincristine (VCR) - Dexamethasone (DEXA) Pulses for Intermediate Risk (IR) Childhood Acute Lymphoblastic Leukemia (ALL) Treated with BFM Based Protocols: Results of the I-BFM-SG ALL IR 95 Study.

Children with TEL/AML1-Positive Acute Lymphoblastic Leukemia (ALL) and Favorable Presenting Features May Benefit from the Use of Vincristine-Dexamethasone (VCR-DXM) Pulses on Top of Antimetabolite-Based Continuation Therapy.

Acute Lymphoblastic Leukemia in Children with Associated Genetic Conditions Other Than Down Syndrome. The AIEOP Experience.

Treatment Intensification of Traditional BFM Therapy with 3 Chemotherapy Blocks and Double Delayed Intensification (Protocol II) Improves Outcome in Infants with High Risk (HR) Acute Lymphoblastic Leukemia (ALL): Results of Two Consecutive AIEOP Studies.

Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group.

Difference in Outcome of Adolescents with Acute Lymphoblastic Leukemia (ALL) Enrolled in Pediatric (AIEOP) and Adult (GIMEMA) Protocols.

Three-Drug Induction and BFM-Type Intensive Consolidation Chemotherapy for Treatment of Standard Risk Childhood Acute Lymphoblastic Leukemia Defined Also by DNA index. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Study ALL-9501.

Genetic evidence for lineage-related and differentiation stage–related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia

Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only